Electroporation and the associated phenomenon of electrofusion have been widely adapted as tools to a broad range of biomedical research and therapy. In this article, we summarize our adaptation of the electroporation and electrofusion technology in two fronts of cancer research and treatment. The first is genetic manipulation of hematopoietic cells for the purpose of cancer treatment. High efficiency transfection methods have been developed to transfect NK cells, peripheral blood stem cells, and bone marrow derived dendritic cells. Hybrids of tumor cells and bone marrow derived dendritic cells have been formed by electrofusion for the purpose of tumor vaccines. The second front is the use of transcutaneous electroporation to deliver anticancer drugs and vaccines across the skin. Methods to extend the upper molecular weight limit of transcutaneous electroporation have been developed. The pro-photosensitizer drug, δ-amino levulinic acid, the anticancer drug methotrexate, and peptide vaccines designed for cancer prevention and immunotherapy have been delivered transcutaneously by electroporation. These studies hold promise for the treatment of cancers in human.
Introduction
Since the first observation of reversible electric breakdown of cell membranes (1-3), many innovative electroporation-related applications have been developed for cancer research and treatment. Electroporation is now a common method of introducing DNA into cells for the purpose of genetic manipulation of tumors (4, 5, 6) . It is also used to deliver transport-deficient drugs into cells, in a new therapeutic treatment known as electrochemotherapy (7, 8) . If electroporation occur in adjacent cells with their electropores in contact, these cells may fuse, resulting in multinuclear cells. Electrofusion has been applied to form cell hybrids.
The basic idea of electroporation is the local, transient electric breakdown of cell membranes induced by an applied pulse. For a cell in a suspension fluid, both the cytoplasm and the suspension fluid contain ions and are relatively conductive as compared to the lipid bilayer material. Being practically electrically insulating, the lipid bilayer of the cell membrane behaves as the dielectric layer of a capacitor when a pulse electric field is applied. The electric field gradient, as represented by equipotential contour lines, is near zero within the highly conducting cell interior, and bunches-up steeply at the two poles of the cell facing the electrodes (Fig. 1) . The charge build-up on either sides of the membrane capacitor may create a breakdown potential of the lipid dielectric material and electric breakdown of the cell membrane may occur. When this happens, molecules smaller than the electropores can move across the membrane barrier. Many theoretical analyses have been published on this topic. Recently, an analogous phenomenon of skin electroporation has been observed (9). The uppermost layer of the skin, the stratum corneum, is electrically insulating while the underlying tissues are highly conductive. If an electric pulse is delivered by an electrode placed above the stratum corneum, and the reference electrode is elsewhere, similar electric field gradient is builded-up across the stratum corneum, as shown in Figure 1 for cell membranes. If the electric field strength exceeds that for the breakdown of the stratum corneum dielectric material, which composes of layers of lipids and keratin, electric breakdown of the stratum corneum may occur. Electroporation of the skin has been documented and the phenomenon has been exploited to deliver drugs and other chemicals trasndermally (9).
In this article, we summarize our adaptation of these phenomena in two fronts of cancer research and treatment. The first is genetic manipulation of hematopoietic cells for the purpose of cancer treatment. The second front is the use of transdermal electroporation to deliver anticancer drugs and vaccines across the skin. These studies, at present on animals, hold promise to treatment of cancers in human.
Gene Delivery to Hematopoietic Cells
Hematopoietic cells hold an important role in many cancer therapies. Being able to genetically modify these cells would make a significant advancement in the efficiency of these therapies. Electroporation technology opens a new possibility to transfect hematopoietic cells that are usually difficult to transfect by conventional means. Being a purely physical technique, electroporation may, in theory, be applicable to any cell types, its efficiency depending only on the size of the cell and dielectric properties of cell components. Many cultured hematopoietic cell lines, such as K562, Jurkat, M2 and myelomas can now be transfected with acceptable efficiency (>20%).
Yet, most primary hematopoietic cells including primary T and B lymphocytes, NK cells, hematopoietic stem cells (peripheral blood CD34 + cells), bone marrow cells, and certain B-lymphomas, are still refractory to conventional electrotransfection. These very cells are the ones considered being most useful in gene therapy and immunotherapy.
In a recent series of experiments, we found that, when subjected to the electrotransfection process, many of the hematopoietic cells died not during pulsing but minutes after. This indicates that electrocution, the disruption of cellular function during the application of the electric field, is not the primary cause of cell death. The delayed action points to secondary effects of electroporation being responsible. We found that colloidal-osmotic swelling was one of the main cause for post-pulse cell mortality. After electroporation, the semi-permeable membranes allow ions and small molecules to equilibrate across the cell boundary, while large macromolecules are retained within. A colloidalosmotic imbalance is thus created, and the cells swell and lyse. The swelling of cells takes tens of seconds to minutes (10, 11) . In a previous study (11, 12) , we found that cell pellets formed by centrifugation provided an excellent environment to limit colloid-osmotic swelling of cells and to reduce the necessary applied electric field strength. Both factors contributed to increasing post-pulse cell viability. Based on this knowledge, we developed a method of pulsing cells in suspension to afford better plasmid DNA transfer, and immediately pelleting the cells after pulse application to protect them from swelling-lysis (11).
In another experiment using L1210/3-3 lymphomas and NFS-70 pro-B cells, which are highly refractory to various transfection methods, we found that the electrotransfection efficiency was limited mainly by apoptosis of electrotransfected cells (13). Apoptosis occurred only when DNA (plasmids or even salmon sperm DNA) was present during electroporation, but was not dependent on the conformation of the DNA used nor the expression of transgenes. Cells pulsed with plasmids coding for luciferase, with or without a promoter (10 4 fold differences in luciferase expression), gave the same apoptotic level. Cells pulsed in the presence of dextran sulfate (MW 500,000) did not undergo apoptosis. The observed programmed cell death was distinct from a minority of instant cell killing by electric pulses. These experiments identified the cause of low transfection efficiency in certain lymphoid cells to be DNA-transport-related apoptosis. The discovery provides a way to improve electrotransfection of these cells (13).
The following are examples of improved transfection of hematopoietic cells.
NK Cells
Natural Killer (NK) cells are one of the cell types that are known to be resistance to conventional methods of transfection. We have succeeded in transfecting NK-L cells by electrotransfection in a custom electroporation chamber (11). Cells were suspended in the growth medium (RMPI-1640 with 20% FCS and 20 ng/ml IL-2) with 250 µg/ml of plasmid DNA and subjected to four 400 µsec pulses at 2.1 kV/cm. After pulse application, cells were immediately transferred to an Eppendorf centrifuge tube and centrifuged at 13,000 x g for 30 sec to form a pellet. The pellet was incubated for a 10 min recovery period at 37º C before re-suspension. The thickness of the pellet is critical for cell survival. The optimal thickness is between 5 to 10 cell layers. Thicker pellets, though better for the prevention of colloidal osmotic swelling, is detrimental to cell viability during incubation.
The post pulse pelleting method improved, by an order of magnitude, the survival of the electrotransfected cells. Plasmids coding for green fluorescence protein or β-gal were used as reporter genes in the evaluation. The transfection efficiency of NK-L cells was improved significantly by the post-pulse pelleting method (Fig. 2) . The transfection efficiency was found to increase with cell density and pellet thickness up to the optimal dimension, as expected from the colloidal-osmotic swelling theory. By applying our knowledge of the biophysical response of cells after electroporation, we were able to transfect cells that were not susceptible to conventional transfection methods.
Hematopoietic Stem Cell
Stem cell implantation technology holds the promise for tissue regeneration and gene therapy. Stem cells have the potential to differentiate into various cell types depending on the microenvironment. By inserting desirable genes into stem cells, one may control the microenvironment for stem cell proliferation and differentiation. For therapeutic purposes, transferring cytokine genes into suitable host stem cells has been used to stimulate local immune functions. Insertion of genes into pluripotent hematopoietic stem cells may achieve lineage specific expression of transgenes following bone marrow transplantation, leading to effective treatments of many genetic and acquired diseases. Another application of gene transfer to hematopoietic stem cells is to confer multi-drug resistance properties to these cells so that they can be retained to repopulate the hematopoietic system during and after high dose chemotherapy (14, 15) . Many of these therapeutic applications require only ex vivo transient transgene expression.
The major obstacle facing these challenges is the low efficiency of gene delivery to human hematopoietic stem cells (16). Although gene delivery technology has been developed and refined for over two decades, primary hematopoietic stem cells are notoriously difficult to transfect (16) . Even about 20-30% of murine hematopoietic stem cells can be genetically modified with a retroviral vector, the corresponding efficiency for larger animal models and humans, however, remains much lower.
We extended our electroporation study to improve the transfection efficiency of human hematopoietic stem cells (17). CD34 + cells, a sub-population of stem cells, were isolated from human donor blood, using a Miltanyi magnetic bead immuno-separation device, or by flow cytometry using a labeled anti-CD34 antibody. Post-pulse pelleting was applied to improve cell viability, since it worked well in other hematopoietic cells. After electroporation, cells either were pelleted or remained suspended for 20 minutes, before they were transferred to StemPro-34 culture medium. We found that the transfection efficiency was limited by the apoptosis of electroporated cells, as was in the case of NFS-70 pro-B cells, MO7E human leukemic cells, and selected subclones of L1210 leukemic cells (13). Apoptosis was determined by propidium iodide/acrindine orange staining, DNA laddering, and was inhabitable by the addition of caspase inhibitors. Without caspase inhibitors, most CD34 + cells underwent apoptosis after electroporation, with or without post-pulse pelleting. Adding the caspase inhibitor fluoromethyl ketone (Boc-Asp-FMK) rescues about 40% of CD34 + cells after pulse application, especially cells that were post-pulse-pelleted ( Fig. 3a ). Using plasmids coding for green fluorescence protein, we found that the transfection efficiency at 24 hours post-pulse increased to 17% if the caspase inhibitor was used ( Fig. 3b ). Without the caspase inhibitor, very few viable cells and practically no transfected cells were detected, with or without post-pulse pelleting. The percentage of viability and transfection could be further improved if incubation was carried out in the presence of stromal cells. Recent studies showed that expression of foreign genes in human hematopoietic CD34 + cells could reach ≥20% by electroporation (18, 19) .
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The combination of post-pulse pelleting and the inhibition of apoptosis can improve the electrotransfection efficiency of human CD34 + stem cells to such a level that it is meaningful to apply to therapies demanding transient gene expression (13, 18). A stem cell transfection level that is sufficient for selection of stable clones for long term gene therapy and tissue reconstruction is now within our reach.
Electrotransfection of Bone Marrow Derived Dendritic Cells (BMDC)
Most tumor cells express tumor-associated antigens (TAA) on their surface. However, many tumor cells escape immune surveillance partly because of their defective major histocompatibility complex (MHC) expression, and low costimulator levels for antigen presentation. This results in apparent inadequacy of cytotoxic T-lymphocyte (CTL) activation and expansion against weakly immunogenic tumors. CTL are most effectively activated by professional antigen-presenting cells (APC) bearing TAA in the context of MHC molecules and co-stimulatory molecules (such as the B7 family molecules). The most immunologically potent of APC are dendritic cells (DC). Upon exposure to antigens, these cells process the antigens and present them in the context of Class I and II MHC to CD8 + CTL and CD4 + T-helper (T H ) cells, respectively, to elicit an immune response.
Delivering genes encoding antigens to dendritic cells is one way to enhance the presentation of the antigen. Transfecting dendritic cells with genes that enhance cells expansion and presentation efficiency would improve immunity against weakly immunogenic tumors.
We extended our electroporation study to improve the transfection efficiency of mouse BMDC. BMDC were generated by culturing female Balb/c mice bone marrow stem cells using an improved culture method (20) . After 10 days of expansion, the BMDC were electroporated by four 400 µs, 2 kV/cm pulses, in the presence of 400µg/ml of pEGFP-N1 plasmid. Following 20 min of incubation, BMDC were transferred to culture medium. We found that the transfection efficiency was limited by apoptosis of electroporated cells. Without caspase inhibitors, the cells expressing green fluorescence protein were about 1-2% at 24 hours after pulsing. When 120 µM of caspase inhibitors fluoromethyl ketone (Boc-Asp-FMK) or (CBZ-Val-Ala-Asp-FMK) was used in the post-pulse culture medium, the transfected cells increased to 15 -20 % (Fig. 4 ). Increasing dendritic cell transfection efficiency offers new opportunities in dendritic cell therapy against cancer.
Electrofusion of Dendritic Cell and Tumor Cells
An attractive strategy to enhance antigen presentation against weakly immunogenic tumors is the use of wholetumor-cell-DC hybrids (dentritomas) as vaccine to stimulate immune response. These hybrid cells would express specific TAA and possess intact immunological molecules for antigen presentation and T-cell activation. Successful application of hybrid cell vaccine produced by fusing DC with tumor cells has been reported (21, 22, 23) . A present challenge is the generation of sufficient quantities of hybrid cells without in vitro expansion, which imposes a limitation in the furtherance of hybrid cell vaccines for treating human cancers. Human vaccination will require a much more rapid and efficient procedure to achieve intervention at a therapeutic level. To attain this goal, conventional electrofusion has been applied to increase the yield of hybrid cells (24, 25).
The commonly use method to form hybrid cells by fusion is by using PEG, which invariably result in random fusion between homogeneous and heterogeneous fusion partner cells. A large portion of the fused cells by the PEG method are non-hybrid and multi-nuclear, and must be eliminated by selection. Typical usable fusion yield is below 10%. We have developed a centrifugation method to fuse cells of heterogeneous size by electrofusion, with high efficiency. The method involves interlayering two types of cells to form a mixed cell pellet, and applies a fusing electric pulse during centrifugation to maximize the heterogeneous fusion yield (26). The pellet method has many advantages over conventional electrofusion methods. First, the fusing cells are protected by centrifugation force from swelling when cell membranes are temporarily permeabilized by the electric pulse. Second, the pellet has a much higher electric resistance then the supernatant, that the pulse field strength is concentrated over cells rather than dissipating in the suspension medium as heat to kill cells. The heterogeneous fusion yield and viability of hybrids, both in the range of 80-90%, are much improved from conventional methods. This method overcomes a serious problem in electrofusion, which is very sensitive to cell size. This method had produced 200 clones of HAT-selected hybridomas in a single operation (26). The method is most suitable for making tumor cells and DC hybrids since, in general, they differ considerably in size.
We recently applied the layered pellet method to make dentritomas from murine bone marrow derive DC (BMDC) and CT-26 colon tumor cells. Approximately 10 7 bone marrow cells were flushed from each femurs of Balb-C mice under sterile condition, and cultured in RPMI 1640+10% FCS with rmGM-CSF (200 U/ml), according to the method of Lutz et al. (20) . On the 9 th day, BMDC were harvested and cultured for a further 2 days in media + 100 U/ml rmGM-CSF and 1826 CpG (1 µg/ml) or LPS (1 µg/ml). CT-26 cells were kept active by passing in Balb-c mice. These two types of cells, with concentrations adjusted to their respective cell volume, were layered alternately, one-layer-at-a-time, by carefully pipetting 0.1 ml into the recess cylinder of the specially made fusion chamber, and centrifuge at 700g for 20 sec in a table top centrifuge. After 6 layers were formed, at a total thickness of about 250 µm, the chamber was filled with media and placed in a specially modified table top centrifuge. Electric pulses of 100-400V and 0.1 msec duration were applied during centrifugation. After pulsing, cells were resuspended and incubated for 20 min for recovery.
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To monitor fusion by fluorescence microscopy and by FACS, the BMDC and CT-26 cells were labeled by the nonexchangeable CellTracker dyes CMFDA (green) and CMTMR (red) (Molecular Probes, Eugene, OR) respectively. Fusion of a smaller green BMCD to a larger red CT26 cell would result in a larger orange-colored cell. This is shown in Figure 5a . Quantitation of the fusion yield by FACS is given in Figure 5b , where fused cells showing both green and red fluorescence is located in the 1 st quadrant. This result for BMDC-CT26 fusion is by no means optimal in terms of cell concentration, layering and electric parameters. It nevertheless show that fusion of BMDC-CT26 was feasible and the initial yield exceeded conventional methods. This high fusion yield technology could provide an answer to the need for rapid and efficient procedure to produce hybrid cells for autologous vaccine treatment of human cancers.
Transcutaneous Delivery of Anti-cancer Drugs and Vaccines
Transcutaneous (sometime referred as transdermal) drug delivery has been applied for treatments of osteoarthritis, soft-tissue rheumatism, tendinitis, local inflammatory conditions and a variety of skin carcinomas. Apart from the convenience and non-invasiveness, the transcutaneous delivery method also utilizes the skin as a "reservoir" that sustains the delivery over a period of days (27), and avoids degradation or metabolism in the gastrointestinal tract or the liver. However, at present, the clinical use of transcutaneous delivery is commonly restricted to small molecules, and very few drugs can be delivered transcutaneously at a viable rate. This is because the skin forms an efficient barrier for most molecules. This restriction becomes more serious as pharmaceutical companies redoubling their effort in searching for effective systems for peptides, proteins and antisense polynucleotide drugs (28).
Recent advances in electroporation and liposome technology suggest a strategy for enhancing transcutaneous transport. If successfully developed, electrically enhanced transcutaneous transport can play a major role in therapeutics. Applications of transcutaneous delivery of genes coding for cytokines may be used to enhance immunotherapy. Introduction of IL-2 or IL-2 producing cells has been shown to enhance the results of electrochemotherapy (29). Transcutaneous transfection by electroporation has been tested recently as an approach to gene therapy of skin aging and other diseases (30). We believe that this emerging technology has a bright future as a drug and gene delivery modality.
Mammalian skin has two layers, the epidermis and the dermis. The epidermis is a stratified squamous keratinizing epithelium. The uppermost stratum of the epidermis is the stratum corneum (SC) which consists of about 20 layers of flattened, enucleate, keratin-filled corneocytes surrounded by lamellae of about 8 lipid bilayers on average. The bilayers consist primarily of cholesterol, free fatty acids and ceramide. The total thickness of the SC varies from 10 to 40 µm, with an average thickness of 20 µm (31, 32). The lipid lamellae are formed and extruded from cells at the underlying stratum spinosum, which are continuously pushed upwards and differentiate into stratum granulosum. At the epidermis-dermis boundary is the stratum basale. The latter three strata, totaling about 100 µm thick, are known as the living epidermis. The dermis is 5-10 times thicker than the epidermis. It consists of connective tissue and vasculature. At the epidermisdermis boundary are Langerhans cells that play an important role in antigen presentation. These cells are part of the immune surveillance system over the body surface.
Since the SC is primarily multilayers of lipids, corneocyte membranes, and matrices of keratin, and constitutes the major electric resistance of the skin, the predominant voltage drop of an applied electric pulse to the skin would develop across the SC. This voltage distribution favors the electroporation of the SC by a given applied pulse. An analysis by Chizmadzhev et al. (32) considered the passages either directly through the electroporated corneocytes and lipid multilayers, or along the tortuous intercellular lipid multilayer routes. The current passing through the narrow initial breakdown route of the SC could causes heat to be generated. The expected instantaneous rise of temperature would depend on the current density within the breakdown path. The dimension of the initial breakdown path is not known, but there are images of the subsequent structural alterations due to the initial breakdown. For instance, local disruption areas are identified as vesicle aggregate patches by electron microscopy (33, 34) and as localized transport regions (LTR) by fluorescence microscopy (35, 36) . Both features appear shortly after the pulse and last minutes to hours afterwards. Vesicle aggregate patch sizes vary from 1-30 µm in diameter, somewhat smaller than the LTR, which range from 40-80 µm in diameter. The fractional area of the vesicle aggregates in the pulsed SC range from 0.05-0.5% while LTR's range from 0.02-1% for 80 V pulses.
Using the fractional area of the vesicle aggregate patches observed by freeze fracture electron microscopy, we calculated the energy density within the (presumed cylindrical) column under the aggregate patch areas caused by an 80 V, 300 µs pulse to be about 100 nJ/ µm 3 . This energy will raise the temperature in this volume by about 100 K. The heat transfer away to the surrounding areas may reduce the actual temperature over time. The initial breakdown pathways through the stratum corneum could be even smaller than the observable columns. The heating rate in an initial aqueous pathway (diameter 10 nm) through the lipid envelope between adjacent corneocytes has been modeled from the energy deposited to be as high as 2x10 8 K/s. This is enough to heat the water within these pathways above the evaporation temperature within some nanoseconds (37). This implies that an 'electropore' heats up itself and the immediate vicinity by current flow. If this analysis holds, the heat generated is sufficient to trigger a phase change of the SC lipids, and facilitates the formation of vesicle patches from the predominantly lamellar structure. The vesicle patches could be related to permeable pores or transport regions (36, 37) . The possible transdermal routes taken by the electric current through the skin is illustrated in Figure 6 . The time for an electropore to reseal depends on the discharging time of the SC, the viscoelastic properties of the SC, as well as the applied electric field strength. The typical recovery time is in the order of seconds to minutes, depends on the pulse voltage and duration, with a voltage threshold at 75-100 V (9, 34). The rate of materials that can be transported through the pore (or any forms of permeabilized areas) is:
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where j is the flux at time t, and J is the transport rate across the membrane during the time T when the pore is open. If diffusion is the main mechanism by which the material passes through the pore,
where K, K' are constants representing the pore-size-dependent hindrance of the material entering the pore, D is the diffusion coefficient, h is thickness of the SC, and ∆C is the concentration gradient. If the mechanism of transport is electrophoresis,
where E and Z are the electric field strength and the charge of the molecules to be transported, respectively (assuming the concentration gradient is large). Thus, the larger the pore sizes and the longer the pore lifetime, the higher is the molecular transport.
Experiments show that transcutaneous transport of small molecules is enhanced by two orders of magnitude by electroporation, as compared to iontophoresis (9, 36). The types of molecules that can be transported transdermally at enhanced rate by electroporation include negatively charged (38) as well as positively charged fluorescent dyes (39), flurbiprofen (40), fentanyl (41), metoprolol (42, 43), dihyrotestersteron (44), alniditan (45), and domperidone (46). Transport of small neutral molecules such as mannitol and glucose (47) was also reported. Transport of larger molecules including modified oligonucleotides (48, 49), human luteinizing hormone releasing hormone (50), heparin, poly-L-lysine (51, 52), lactalbumin and IgG (53), as well as antigenic peptides (54) also have been reported. This technique holds great promise to enhance transcutaneous drug delivery. Some examples of our effort to deliver anticancer drugs and vaccines by transcutaneous electroporation are given below.
Increase the Transcutaneous Flux and Extending the Molecular Weight Limit by Using Lipid Enhancers
The present transcutaneous delivery by electroporation is still restricted mainly to small molecules. The limitation is set by the size, number and the lifetime of the electropores. The molecular weight cutoff was determined, using FITC-dextrans, to be about 10 kD (55, 56). Increasing the upper limit of the molecular size is desirable because many drugs and biological modifiers, including peptides and polynucleotides, are still beyond this limit. Attempts have been made to increase the upper limit by applying keratolytic molecules (sodium thiosulfate, urea, heperin) (53, 57) simultaneously with electroporation, to enlarge the transport channels. The idea is to cause more and longer-lasting transportation routes by the applied pulses. By studying the phase behavior of SC lipid, we developed a strategy to use saturated anionic lipids to prolong the lifetime and perhaps enlarge the size of electropores. Because of their net negative charge, anionic lipids could be driven into the SC by negative pulses. Anionic lipids prefer loosely packed multilamellae (58), and are prone to develop and retain vesicular form upon physical perturbation, such as electric pulses. Saturated anionic lipids are expected to mix and retain better with predominantly saturated SC lipids. We therefore expect that the presence of saturated anionic lipids in SC would lower the breakdown threshold voltage and/or prolong the recovery. Enhancing and prolonging the vesicle column formation during and after electroporation is likely to enhance molecular transport.
To test the importance of lipid acyl chain saturation and charged headgroups in lipid-enhanced transport and their incorporation in the stratum corneum (SC), we used dimyristoyl-phosphatidylserine (DMPS), dioleoyl-phosphatidylserine (DOPS) and dioleoyl-phosphatidylglycerol (DOPG) as exogenous lipids. We measured and compared the electric pulse induced transport of fluorescein-labeled Dextran (4000 M.W.) in the presence or the absence of liposomes made of these anionic lipids (at 0-5 mg/ml of lipid). Figure 7 shows that the Dextran transport increases with increasing concentration of liposomes present. The enhancement of Dextran transport by over two orders of magnitude was achieved with added saturated DMPS as against the unsaturated DOPS and DOPG. We also found that DMPS was retained in the SC much more than the other two. Retention of the saturated anionic lipid helps to prolong the lifetime of electropores, as evident by the recovery of electrical resistance (36). These exogenous lipids were indeed found, by fluorescence microscopy, to be located in the local transport regions (36). The use of anionic lipid also extended the upper molecular weight limit of transportable molecules beyond 4000 Dalton (56). By using saturated anionic lipid-enhancers for transdermal transport by electroporation, we are able to transport 4 kD molecules at an equivalent flux of 275 µg/cm 2 /min, and 9 kD molecule at ~10% of this rate. Peptide drugs, metabolic regulators such as insulin (59), and vaccines (54), as well as antisense polynucleotides (60) of these sizes can now be transported through the skin at practical rates by electroporation, without long lasting skin damage.
Delivery of the Pro-photosensitizer Drug, δ-amino Levulinic Acid (ALA), for Photodynamic Therapy
Photodynamic therapy (PDT) is a technique which utilizes light-activated cellular damage induced by a photosensitizers in an oxygen-rich environment for the treatment of certain types of cancer (61). Topical administration of photosensitizers is restricted by poor diffusion of these charged or hydrophilic molecules across the stratum corneum (SC). We used electric pulses to increase the transdermal transport of ALA, a precursor to the photosensitizer protoporphyrin IX (PpIX). Electrodes were attached to the surface of fresh, excised full-thickness porcine skin, or to the dorsal surface of mice. An aqueous solution of ALA was applied to the skin beneath the electrodes. Electrical pulses (up to 125 volts per skin passage) of 0.1 to 1.0 msec at 1 to 100 Hz were applied for 15 to 60 minutes. To utilize the long lifetime of the electropores for electromotive or electroosmotic transport, a DC potential of 6 volts was applied at the same time in some in vivo cases. The penetration of ALA was determined using 14 C-labeled ALA. Most radioactivity was detected in the 120-130 µm depth from the skin surface (62). Intracellular conversion of ALA to PpIX enabled delivery to be monitored also by fluorimetry. Penetration of ALA in vivo was assayed by measuring the relative fluorescence of protoporphyrin IX in dissolved skin samples. As the electrical dose (transdermal voltage × frequency × pulse width × treatment duration) increased, there was an increase in the depth of penetration of ALA. A greater than two-fold enhancement of PpIX production with electroporative delivery was seen, as compared to that obtained with passive (diffusion) delivery. Superimposition of a DC potential over the pulses resulted in a nearly five-fold enhancement of PpIX production vs. the levels achieved with passive delivery (Figure 8 ). PpIX lev-els were higher than the sum of the amount of PpIX detected after pulse-alone and DC potential-alone delivery. Clearly, the electromotive or electroosmotic delivery of ALA was enhanced by the formation of electropores by the pulse electric field. In addition, it is expected that electric pulses will act to perforate cells in vivo, leading to increase cellular uptake of the photosensitizer. Increasing the efficiency of transdermal and intracellular delivery of photosensitizers will also act to minimize the possibility of systemic side effects if the drug is to be delivery systemically.
Delivery of the Anticancer Drug Methotrexate
Methotrexate (MTX) is the most commonly used antimetabolite in cancer treatment. It is used in treatment regimens for childhood leukemia, head and neck cancer, breast cancer, and osteogenic sarcoma. A major concern in MTX therapy is the induction of liver fibrosis. Therefore, topical application is desirable if sufficient doses can be given locally. The negative charge of MTX at neutral pH hinders its transport though the skin by diffusion (63). Transcutaneous delivery of MTX by electroporation would help to overcome the obstacle.
We applied negative pulses and negative DC potential to enhance the transport of MTX to porcine skin. A solution of MTX was place under the cathode, and sixty 1 msec long pulses at 100 V per skin passage were applied at 1 Hz. The flux of MTX was measured using 3 H-labeled MTX. The depth profile of delivery was determined by radioactivity measurement of sections cut parallel to the skin surface. Compared to transport by surface adhesion and diffusion, electric pulses enhanced the delivery by ~5 fold if a DC potential of 8V was applied concurrently with high field pulses. The flux is equivalent to 400 µg/cm 2 /hr, much high-
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Technology er than by iontophoresis (63). The distribution of MTX was within the first millimeter from the skin surface where most of the skin disease sites located.
Delivery of Peptide Vaccines for Cancer Prevention and Immunotherapy
Even though most tumor cells are known to express tumorassociated antigens (TAA) on their surface, providing targets for immunotherapy, many tumors still escape immune surveillance or become immune tolerant, partly because of inadequate presentation of TAA to activate cytotoxic T-lymphocyte (CTL) response. A large number of antigen-presenting-cells (APC) are strategically located in the epidermis for antigen exposure. If a large number of these APC are induced to process and present TAA, anti-tumor immune response would be significantly enhanced. Electroporation has the advantage that TAA molecules can be delivered through the skin over a wide area, and that TAA are not only transported to a defined depth of the skin but also delivered into a large number of cutaneous APC such as dendritic cells (DC) and Langerhans cells (LC).
HER-2/neu protooncogene is overexpressed in 20-40% of invasive breast cancer, and the antigenic protein overexpression is detectable in 50-60% of ductal carcinoma (64). A high percentage of these patients have HER-2/neu specific antibodies, implying that immunity against this TAA had developed. One of the major obstacles to effective application of immunotherapy against breast cancer using this antigen is the apparent inadequacy of cytotoxic T-lymphocyte (CTL) activation and expansion against weakly immunogenic tumors. The peptide segment (9-369) KIFGSLAFL of the antigenic protein was shown to be able to elicit an HLA-A2.1-restricted CTL response against HER-2/neu expressing tumor cells (65, 66) . This peptide has been used as a vaccine against HER-2/neu expressing tumors.
To test the potential as vaccines deliverable by transcutaneous electroporation, We synthesized the peptide KIFGSLAFL, and as a control, the K b -binding OVA peptide, SIINFEKL. In order to measure the quantity of peptides that can be delivered transdermally by electroporation, some of the OVA peptide was labeled with rhodamine. This peptide carries 1 net negative charge when the lysine is linked to a rhodamine. The transport across excised murine skin was measured using a Vertical Diffusion Holder. The donor chamber contains the cathode while the receiver chamber contains the anode. After fifteen 1 msec pulses at 100V were applied at 1 Hz, the peptide transported to and through the skin was 3 fold of that by diffusion alone. Application of a simultaneous 9VDC potential enhanced the transport further. In the presence of saturated anionic lipid and with thirty 1 msec pulses at 100V, the transport of the peptide was 7-fold higher than that by diffu-sion alone, and reached about 0.3 µg/cm 2 . Increasing the number of pulses resulted in further increasing the transport proportionally. The amount of peptide vaccine that can be delivered were sufficient to generate an immune response (54). Direct delivery of peptide vaccine by electroporation offers an alternative to intradermal injection of DNA vaccine and then applying enhancing electroporation (67).
Conclusion
As a biophysical technique, electroporation and the associated phenomenon of electrofusion have been widely adapted as a tool to a broad range of cancer research and treatment. An outstanding example is electrochemotherapy. Electro-genetherapy is rapidly emerging as a new branch of gene therapy. The limitations of the technology are quickly realized as the field mature. High mortality in certain target cells (sometime referred as electro-toxicity) posts a boundary to broader application, while the molecular size limit in transcutaneous transport is another obstacle. It requires proper understanding of the biophysical mechanism of electroporation to devise novel approaches to break through these barriers. Advances in certain fronts are summarized in this article.
